SCHEMBL1233804

SCHEMBL1233804

CCCNC(=O)c1cccc(B(O)O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.65
SMN1; SMN2 Q16637 2/20 0.59
ALDH1A1 P00352 3/20 0.58
POLB P06746 1/20 0.58
ERN1 O75460 2/20 0.53
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ROCK2 O75116 1/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
NAAA Q02083 1/20 0.46
GAA P10253 3/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
LMNA P02545 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 1/20 0.45
TP53BP1 Q12888 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL177577 0.91 SMN1; SMN2 (0.74) L3MBTL1SMN1; SMN2ALDH1A1POLBNAAA
SCHEMBL15985302 0.90 SMN1; SMN2 (0.68) L3MBTL1SMN1; SMN2ALDH1A1POLBNAAA
SCHEMBL3031782 0.87 SMN1; SMN2 (0.50) L3MBTL1SMN1; SMN2ALDH1A1POLBKMT2A
SCHEMBL15985305 0.86 KMT2A (0.50) L3MBTL1SMN1; SMN2ALDH1A1POLBNPC1
SCHEMBL5083356 0.86 HPGD (0.51) L3MBTL1SMN1; SMN2ALDH1A1POLBKMT2A
SCHEMBL955684 0.85 HPGD (0.56) L3MBTL1SMN1; SMN2ALDH1A1HPGD
SCHEMBL13763531 0.85 L3MBTL1 (0.80) L3MBTL1SMN1; SMN2ALDH1A1POLBERN1
SCHEMBL2555324 0.84 SMN1; SMN2 (0.51) L3MBTL1SMN1; SMN2ALDH1A1KMT2AMEN1
Dimethylamine SCHEMBL1082247 0.84 SMN1; SMN2 (0.48) L3MBTL1SMN1; SMN2ALDH1A1POLBKMT2A
SCHEMBL15330249 0.84 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-9562033-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-02-07 US disclosed
US-9562033-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-02-07 US disclosed
US-9562033-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-02-07 US disclosed
US-20160039783-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses HIVIH (FR) 2016-02-11 US disclosed
US-20160039783-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses HIVIH (FR) 2016-02-11 US disclosed
US-20160039783-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses HIVIH (FR) 2016-02-11 US disclosed
EP-2903983-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2015-08-12 EP disclosed
US-20140349970-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2014-11-27 US disclosed
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-20110190489-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-08-04 US disclosed
US-7897609-B2 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-7888349-B2 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-02-15 US disclosed
US-20090069314-A1 Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-03-12 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed
EP-1968587-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS Coley Pharmaceutical, Inc. (US) 2008-09-17 EP disclosed
US-20070259907-A1 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2007-11-08 US disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 US disclosed
US-20070167476-A1 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds 3M INNOVATIVE PROPERTIES COMPANY 2007-07-19 US disclosed
WO-2007075468-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259907-A1 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES IL2, TSLP, IFNG L3MBTL1 2951/4885SMN1; SMN2 4726/4885ALDH1A1 521/4885
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon IFNG, IFNAR1, EIF2AK2 L3MBTL1 2979/4885SMN1; SMN2 4065/4885ALDH1A1 1275/4885
US-20070167476-A1 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds IL4, IL2, IL5 L3MBTL1 4324/4885SMN1; SMN2 3137/4885ALDH1A1 401/4885
US-20090069314-A1 Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods IFNG, IRF3, IFNAR1 L3MBTL1 2691/4885SMN1; SMN2 4365/4885ALDH1A1 1350/4885
US-20140349970-A1 NOVEL TRICYCLIC COMPOUNDS CCNI, IL2, IL4I1 L3MBTL1 4805/4885SMN1; SMN2 4280/4885ALDH1A1 305/4885
US-20070219228-A1 Aryl substituted imidazonaphthyridines IL2, IRF3, EIF2AK2 L3MBTL1 3174/4885SMN1; SMN2 3309/4885ALDH1A1 1178/4885
US-20110190489-A1 Novel Tricyclic Compounds CCNI, IL2, IL4I1 L3MBTL1 4805/4885SMN1; SMN2 4280/4885ALDH1A1 305/4885
US-20160039783-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses POLRMT, MAVS, EIF2AK2 L3MBTL1 1958/4885SMN1; SMN2 3115/4885ALDH1A1 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.